-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Deki Pharmaceuticals has recently submitted applications for the listing of selinexor for three types of hematoma adaptations, including multiple myeloma and diffuse large B-cell lymphoma.
, five treatment options for selinexor for multiple myeloma and diffuse large B-cell lymphoma have been included in the Guidelines of the National Comprehensive Cancer Network (NCCN®).
As the world's first approved SINE compound, selinexor can cause in-nucleus storage and activity of tumor suppressor and other growth-regulating proteins, as well as lower levels of a variety of carcinogenic proteins in the plasma, and induce apoptosis of large numbers of solid and blood tumor cells in vitro and in vivo without affecting normal cells.
clinical studies have shown that ATG-010 has obvious efficacy and safety control for a variety of hematomas and solid tumors.
note: There are deletions in the original text